We De-LIVER on More Livers: Hepatitis B-Positive Transplant Donors and Recipients

December 17, 2020

Currently, there are over 12,000 people on the waiting list to receive a liver in the US, and around 17 people die each day waiting on a transplant. Because of this severe organ shortage in the US, organs that were previously rejected due to infection with different types of hepatitis are now being considered and used, requiring additional treatment for hepatitis B to protect the new liver being transplanted. Guidelines for treatment of hepatitis B infected recipients and donors is addressed by two guidelines: American Society of Transplantation (AST) and American Association for the Study of Liver Diseases (AASLD). There are antiviral agents and hepatitis B immunoglobulin available for treatment of hepatitis B. However, there are often many questions about when to use which agents. This presentation will review the primary literature behind the use of antivirals and hepatitis B immunoglobulin in hepatitis B positive transplant recipients and donors.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Discuss diagnosis of hepatitis B
  2. Compare the agents used to treat hepatitis B in the setting of patients receiving a liver transplant
  3. Evaluate the literature on the use of antiviral agents and hepatitis B immunoglobulin to prevent hepatitis B in patients receiving a liver transplant and recognize their place in practice

Pharmacy technician learning objectives

  1. Recognize brand/generic names of the antiviral agents used in the treatment of hepatitis B
  2. Identify the different dosage forms of the antiviral agents
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance
Course opens: 
12/17/2020
Course expires: 
01/31/2021
Event starts: 
12/17/2020 - 12:00pm
Event ends: 
12/17/2020 - 1:00pm
Cost:
$0.00
Ochsner Medical Center
New Orleans, LA
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose
 
Planning committee members
Stephanie Anders, PharmD, BCPS
Clinical Pharmacist
Ochsner Medical Center
 
Bailey Wise, PharmD, BCPS
Clinical Pharmacist
Ochsner Medical Center
 
Course reviewer
James Lichauer, PharmD, BCPS, FASHP
PI Program Director, Pharmacy
Vizient
 
Presenter
Olivia Griffis, PharmD
PGY-1 Pharmacy Practice Resident
Ochsner Medical Center

 

Joint Accreditation Statement:
 
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
____________________________________________
 
Designation Statements:
 
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-20-232-L01-P
Universal Activity Number: JA0006103-9999-20-232-L01-T
CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance

Price

Cost:
$0.00
Please login or register to take this course.